In controlled trials, it reduced HbA1c levels with comparable efficacy to standard treatment
Clinical guidelines continue to reflect this nuance
A negative PCAC outcome today leaves that market intact as the only practical access point for these compounds
An early work, presented in 1995 by Dentico and colleagues, evaluated the effect of 30-day administration of high doses of intravenous or intramuscular GSH on liver cytolysis indexes in patients with chronic steatosic liver disease ( A subsequent study of Irie and colleagues in 2016 showed that the use of oral glutathione, at a daily dosage of 300 milligrams per day, may prevent NASH progression from NAFLD ( The study by Honda et al., conducted in 2017, was an open-label, single-arm, multicentre pilot study that evaluated the therapeutic effect of oral glutathione administration (300 mg/day) in patients with NAFLD through the evolution of biochemical indices (ALT) and liver fat levels assessed by VCTE ( These preliminary studies suggest a potential therapeutic effect of oral administration of GSH in NAFLD
Um, and if we, if were just giving it away because were going on a drastic weight loss diet, thats, you know, were, were quite literally aging our body 10 years
